Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iVOCAL: IDH1 Vaccine and Vorasidenib in Recurrent Astrocytoma
NCT07877415Phase 1Not yet recruiting
- Sponsor
- Heidelberg University
- Start
- Jan 2027
- Primary completion
- Dec 2032
01
Overview
Phase 1, randomised, open-label trial of IDH1R132H-vac and vorasidenib in astrocytoma (5 arms), sponsored by Heidelberg University. Primary endpoint: Regime-limiting toxicity at 37 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
IDH1R132H-vacvorasidenib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT07877415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877415.